title: Neoadjuvant chemotherapy with doxorubicin and cisplatin in malignant fibrous histiocytoma of bone: A European Osteosarcoma Intergroup study.
abstract: OBJECTIVE
  Studies involving small case series have suggested that malignant fibrous histiocytoma of bone (MFH-B) is a chemosensitive tumor and that chemotherapy may improve survival. In this study, we evaluated clinical and pathologic response rates and survival in a series of patients treated with a consistent chemotherapy regimen of doxorubicin and cisplatin (DOX/DDP).
  
  
  METHODS
  Study patients were required to have biopsy-proven MFH-B, no previous chemotherapy, and primary or metastatic measurable disease and to be </= 65 years of age. Treatment consisted of doxorubicin 25 mg/m(2)/d days 1 through 3 and cisplatin 100 mg/m(2) by 4-hour intravenous infusion every 3 weeks for six cycles. In patients with operable primary tumors, chemotherapy was planned to start within 42 days of biopsy, with definitive surgery performed after three cycles.
  
  
  RESULTS
  Forty-one patients had operable nonmetastatic limb sarcomas, and 23 (56%) completed six chemotherapy cycles. Limb salvage was possible in 33 patients (80%), and 16 (42%) of 38 assessable specimens showed a good pathologic response (>/= 90% necrosis). Median time to progression was 56 months, and the 5-year progression-free survival rate was 56% (95% confidence interval [CI], 40% to 72%). Median survival time was 63 months, and the 5-year survival rate was 59% (95% CI, 41% to 77%). Patients with a good pathologic response had longer survival times and times to progression than did those with a poor response. Also treated were two patients with locally recurrent and nine with metastatic disease, and these patients had a median survival time of 17.5 months.
  
  
  CONCLUSIONS
  Our study suggests that adjuvant or neoadjuvant chemotherapy with DOX/DDP is beneficial in MFH-B. Good pathologic response rates and survivals are quite comparable with those for osteosarcoma, a related bone tumor for which adjuvant or neoadjuvant chemotherapy is an accepted practice.
authors.affiliation: London Regional Cancer Centre, London, Ontario, Canada. vbramwell@lrcc.on.ca
authors.forename: V H
authors.initials: VH
authors.lastname: Bramwell
authors.forename: W P
authors.initials: WP
authors.lastname: Steward
authors.forename: M
authors.initials: M
authors.lastname: Nooij
authors.forename: J
authors.initials: J
authors.lastname: Whelan
authors.forename: A W
authors.initials: AW
authors.lastname: Craft
authors.forename: R J
authors.initials: RJ
authors.lastname: Grimer
authors.forename: A H
authors.initials: AH
authors.lastname: Taminau
authors.forename: S R
authors.initials: SR
authors.lastname: Cannon
authors.forename: A J
authors.initials: AJ
authors.lastname: Malcolm
authors.forename: P C
authors.initials: PC
authors.lastname: Hogendoorn
authors.forename: B
authors.initials: B
authors.lastname: Uscinska
authors.forename: A L
authors.initials: AL
authors.lastname: Kirkpatrick
authors.forename: D
authors.initials: D
authors.lastname: Machin
authors.forename: M M
authors.initials: MM
authors.lastname: Van Glabbeke
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D018450:Disease Progression; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D018219:Histiocytoma, Benign Fibrous / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009364:Neoplasm Recurrence, Local; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D004317:Doxorubicin; D002945:Cisplatin